Evidence mapPaperPMID 40648740Full record

ReviewNanomaterials (Basel, Switzerland)2025

Evaluating Biocompatibility: From Classical Techniques to State-of-the-Art Functional Proteomics.

Ana Nuño-Soriano, Carlota Arias-Hidalgo, Enrique Montalvillo, Rafael Góngora, Ángela-Patricia Hernández, Pablo Juanes-Velasco, Manuel Fuentes

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana Nuño-SorianoTranslational and Clinical Research Program, Cytometry Service, NUCLEUS and Department of Medicine, Cancer Center Research (IBMSS-CSIC), University of Salamanca, 37008 Salamanca, Spain.ORCID 0009-0006-7051-3460
Carlota Arias-HidalgoTranslational and Clinical Research Program, Cytometry Service, NUCLEUS and Department of Medicine, Cancer Center Research (IBMSS-CSIC), University of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0002-4131-3420
Enrique MontalvilloTranslational and Clinical Research Program, Cytometry Service, NUCLEUS and Department of Medicine, Cancer Center Research (IBMSS-CSIC), University of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0003-1190-7428
Rafael GóngoraTranslational and Clinical Research Program, Cytometry Service, NUCLEUS and Department of Medicine, Cancer Center Research (IBMSS-CSIC), University of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0002-8046-4301
Ángela-Patricia HernándezTranslational and Clinical Research Program, Cytometry Service, NUCLEUS and Department of Medicine, Cancer Center Research (IBMSS-CSIC), University of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0002-5585-9918
Pablo Juanes-VelascoTranslational and Clinical Research Program, Cytometry Service, NUCLEUS and Department of Medicine, Cancer Center Research (IBMSS-CSIC), University of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0001-9435-2952
Manuel FuentesTranslational and Clinical Research Program, Cytometry Service, NUCLEUS and Department of Medicine, Cancer Center Research (IBMSS-CSIC), University of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0002-7305-3766

Funding

CSIC's Global Health Platform SGL2103027European Commission -NextGenerationEU EU 2020/2094Institute of Biomedical Research of Salamanca FI21/01545Institute of Biomedical Research of Salamanca FI22/0000323JCYL PhD Program and Fondo Social Europeo (FSE+) scholarship EDU/1009/2024Junta de Castilla y León 07.04.467B04.74011.0NanoMedicine CSIC HUB 202180E048
6 · The paper itself

Abstract

Biocompatibility remains a central issue for introducing biomaterials and nanomedicines into the clinic, requiring safety, functionality, toxicity prevention, and the control of foreign body reactions. Therefore, it is necessary to evaluate multiple biomaterial parameters and molecular interactions affecting cell functions, like apoptosis, adhesion, proliferation, or spreading, as well as intracellular signals and cellular microenvironment status. Although conventional well-established in vitro techniques are helpful at the first stages of bio and nanomaterials development, high-throughput techniques expand the screening and designing possibilities. This review presents high-throughput functional proteomics approaches, focused on protein microarrays and mass spectrometry techniques, for the evaluation of biocompatibility in the new era of biomedicine.

Indexed as

biocompatibilitybiomaterialsfunctionalitynanomedicinesnanoscaleproteomicstoxicity

Identifiers

PMID40648740
PMCPMC12250899

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.